N-(6-piperidin-1-ylsulfonyl-1,3-benzothiazol-2-yl)naphthalene-2-carboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-(6-piperidin-1-ylsulfonyl-1,3-benzothiazol-2-yl)naphthalene-2-carboxamide
• 化学式: C₂₃H₂₁N₃O₃S₂
• 分子量: 451.6
• InChiKey: JMOJBTSEZKZDKC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  116
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-1" PATHWAY AND METHODS OF USE THEREOF<br/>[FR] ACTIVATEURS DE LA VOIE DU GÈNE INDUCTIBLE PAR L'ACIDE RÉTINOÏQUE "RIG-1" ET LEURS PROCÉDÉS D'UTILISATION
  申请人：KINETA INC

  公开号：WO2020033782A1

  公开（公告）日：2020-02-13

  The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.

  本发明涉及式(I)化合物，该化合物是RIG-I通路的激活剂。
• ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：Kineta, Inc.

  公开号：US20170057978A1

  公开（公告）日：2017-03-02

  Disclosed herein are compounds, pharmaceutical compositions, and related methods for the treatment of viral infection, including RNA viral infection in subjects. The compounds, pharmaceutical compositions, and methods can modulate the innate immune antiviral response in vertebrate cells, including activating the RIG-I pathway.
• ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-I" PATHWAY AND METHODS OF USE THEREOF
  申请人：Kineta Immuno-Oncology LLC

  公开号：US20200071316A1

  公开（公告）日：2020-03-05

  The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.
• US9884876B2
  申请人：——

  公开号：US9884876B2

  公开（公告）日：2018-02-06
• [EN] ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS ANTI-VIRAUX, COMPOSITIONS PHARMACEUTIQUES ET MÉTHODES D'UTILISATION DE CEUX-CI
  申请人：KINETA INC

  公开号：WO2015172099A1

  公开（公告）日：2015-11-12

  Disclosed herein are compounds, pharmaceutical compositions, and related methods for the treatment of viral infection, including RNA viral infection in subjects. The compounds, pharmaceutical compositions, and methods can modulate the innate immune antiviral response in vertebrate cells, including activating the RIG-I pathway.